Please login to the form below

Not currently logged in
Email:
Password:

MDR-TB

This page shows the latest MDR-TB news and features for those working in and with pharma, biotech and healthcare.

A Schengen area of healthcare

A Schengen area of healthcare

aimed at eradicating diseases such as multidrug resistant tuberculosis (MDR-TB); and to create a level playing field between member states that will allow for a cooperative response to health threats. ... For example, the spread of MDR-TB within the EU

Latest news

  • Study shows Otsuka's TB drug works even in worst cases Study shows Otsuka's TB drug works even in worst cases

    Typically, it occurs in patients who do not take their drugs as indicated by their doctor, and was first identified as a sub-category of MDR-TB in 2006. ... Around 9% of the 480, 000 MDR-TB cases estimated to have occurred in 2013 are thought to actually

  • R&D productivity takes off R&D productivity takes off

    nitro-dihydro-imidazooxazole drug for multidrug-resistant tuberculosis (MDR-TB); Gilead Sciences' Zydelig (idelalisib) for certain types of leukaemia and lymphoma, which inhibits a protein that plays a role in the

  • Novartis' Bexsero triumphs at UK Prix Galien Novartis' Bexsero triumphs at UK Prix Galien

    The novel treatment for pulmonary multi‐ drug resistant tuberculosis (MDR‐ TB) is administered by directly observed therapy and indicated as part of combination therapy in adults with pulmonary MDR‐ TB. ... MDR‐ TB and preventing progression to

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    According to the World Health Organization (WHO), there are about 170, 000 deaths globally each year due to MDR-TB. ... Both trials arms also received other therapies. Akihiko Otsuka, chairman of Otsuka, said that MDR-TB remained a “ serious problem”

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Multi drug-resistant TB (MDR-TB) is defined as resistance to the gold standard treatment of isoniazid and rifampicin. ... Bedaquiline has been approved for use as part of combination therapy, in adult patients with MDR-TB and has been shown to be active

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics